doi: 10.1007/s11136-004-9567-x
Liraglutide was finally approved in 2010 for the treatment of patients with type 2 diabetes unable to regulate their blood sugar with other insulin medications (Gilbert, Rosenthal, Jan 2024)
A recent cross-sectional study involving 124 participants indicated that 56% of patients still exhibited elevated residual gastric contents despite halting incretin agonists for a minimum of 7 days, thus challenging the practice of discontinuing long-acting GLP-1 RAs solely for this duration prior to surgery [19]
Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH
7 Powerful Morning Routines for GLP1 Success to Support a Positive Weight Management Journey
Additionally, in a post-hoc analysis of the SURPASS-4 trials, tirzepatide showed a slower rate of eGFR decline and lower urinary albumin creatinine values as compared to patients who were treated with glargine insulin [75, 76]
